0/2小时即时高敏肌钙蛋白算法验证:美国多中心研究
本研究为美国三中心前瞻性队列,纳入578例无STEMI且至少开具一次hs-cTnI的成人急诊患者,同步采集血样进行i-STAT即时hs-cTnI与中心实验室hs-cTnI检测。主要终点为专家裁定的索引性心肌梗死(MI)。原始澳大利亚0/2小时算法排除区NPV为99.4%(95%CI 97.7%-99.9%),效率54.8%,纳入区PPV 62.7%(95%CI 48.1%-75.9%)。优化算法(调整切点)将效率提升至60.0%,NPV 99.4%(95%CI 97.9%-99.9%),PPV 74.4%(95%CI 58.8%-86.5%)。
要点
- 原始0/2小时算法排除区NPV 99.4%(95%CI 97.7%-99.9%),可安全排除54.8%的患者。
- 原始算法纳入区PPV仅62.7%(95%CI 48.1%-75.9%),低于优化目标PPV≥65%。
- 优化0/2小时算法效率提升至60.0%,NPV 99.4%(95%CI 97.9%-99.9%),PPV 74.4%(95%CI 58.8%-86.5%)。
- 观察区占36.3%(210/578),其中4.3%(9/210)裁定为索引性MI。
- 研究人群:48%女性,40%非白人,中位年龄60岁(IQR 50-70),索引性MI发生率7.4%(43/578)。
适用人群与场景
- 美国三个急诊科(2025年2月至9月)前瞻性纳入的成人患者,无STEMI且至少开具一次hs-cTnI检测。
- 排除STEMI患者;原文未提及其他排除标准。
- 适用场景为急诊科疑似急性冠脉综合征的初始评估与0/2小时快速排除/纳入。
诊断标准与关键阈值
- 使用i-STAT 1分析仪(Abbott Laboratories)进行即时hs-cTnI检测,同步以Beckman Coulter中心实验室hs-cTnI作为临床裁定依据。
- 原始澳大利亚0/2小时算法:排除区NPV 99.4%,纳入区PPV 62.7%;观察区占36.3%。
- 优化0/2小时算法:调整切点后效率60.0%,NPV 99.4%,PPV 74.4%;优化目标为维持NPV≥99%且PPV≥65%。
- 原文未给出具体切点数值(ng/L)及0小时/2小时的具体阈值。
处置流程与药物剂量
- 第一步:对无STEMI且计划检测hs-cTnI的急诊成人,同时采集血样进行i-STAT即时hs-cTnI和中心实验室hs-cTnI检测。
- 第二步:按0/2小时算法在0小时和2小时时间点使用i-STAT POC hs-cTnI结果进行分类(排除区、观察区、纳入区)。
- 第三步:排除区患者(原始算法54.8%,优化算法60.0%)可考虑排除索引性MI;观察区患者需进一步观察/检测;纳入区患者按MI处理。
- 原文未提供具体药物剂量、给药途径或治疗方案。
红旗征与不能漏的情况
- STEMI患者不适用该0/2小时算法(原文明确排除STEMI)。
- 观察区患者中4.3%(9/210)裁定为索引性MI,不能仅凭观察区分类而漏诊。
- 原始算法纳入区PPV仅62.7%,存在假阳性可能,需结合临床综合判断。
研究设计与关键结果
- 研究类型:前瞻性队列研究,美国三中心,样本量578例,研究期2025年2月至9月。
- 人群特征:48%(279/578)女性,40%(233/578)非白人,中位年龄60岁(IQR 50-70),索引性MI 7.4%(43/578)。
- 原始0/2小时算法:效率54.8%(317/578),排除区NPV 99.4%(95%CI 97.7%-99.9%),纳入区PPV 62.7%(95%CI 48.1%-75.9%),观察区36.3%(210/578)中MI 4.3%(9/210)。
- 优化0/2小时算法:效率60.0%(347/578),NPV 99.4%(95%CI 97.9%-99.9%),PPV 74.4%(95%CI 58.8%-86.5%)。
证据类型、等级与局限
- 证据类型:前瞻性多中心队列验证研究(原文未给出证据等级或推荐强度)。
- 局限:原文未明确列出局限;设计上为单国三中心、样本量578例、非随机、算法切点为优化调整而非预设。
对床旁实践的改变
- 原始算法纳入区PPV偏低(62.7%),直接纳入可能增加假阳性;优化算法将PPV提升至74.4%但需进一步外部验证。
- 观察区患者仍有4.3%的MI风险,不能随意离院,需按流程继续观察或检测。
- 不适用于STEMI患者;原文未提及其他不适用人群。
指南或共识出处
- 原文未提及指南或共识名称;本研究为验证澳大利亚衍生算法的多中心队列研究(Acad Emerg Med),试验注册号NCT06899776。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: A 0/2-h algorithm for the i-STAT point-of-care (POC) high sensitivity troponin I (hs-cTnI) assay was recently derived in Australia. The objective of this study was to validate and optimize the performance of the 0/2-h algorithm in a multisite U.S. Emergency Department (ED) cohort.
METHODS: A prospective cohort study was conducted at three U.S. EDs (February-September 2025). Adults without STEMI and at least one hs-cTnI ordered were accrued. Blood samples were collected simultaneously for POC hs-cTnI measurement on an i-STAT 1 analyzer (Abbott Laboratories) and central laboratory hs-cTnI measurement (Beckman Coulter). The primary outcome was index myocardial infarction (MI), adjudicated by experts using clinical hs-cTnI measures. Diagnostic performance of the Australian 0/2-h algorithm was assessed by calculating negative and positive predictive values (NPV, PPV) with associated 95% confidence intervals. Efficacy, defined as the proportion of patients classified into the rule-out zone, was calculated. Algorithm optimization tested modified cut points to increase efficacy while maintaining NPV ≥ 99% and achieving PPV ≥ 65%.
RESULTS: During the study period, 578 patients with complete 0/2-h algorithm assessments were accrued. These patients were 48% (279/578) female, 40% (233/578) non-White, with a median age of 60 years (IQR: 50-70). Index MI occurred in 7.4% (43/578). Algorithm efficacy was 54.8% (317/578) and 8.8% (51/578) were classified to the rule-in zone. Among patients ruled-out, the NPV was 99.4% (95% CI: 97.7%-99.9%). The rule-in zone was associated with a PPV of 62.7% (95% CI: 48.1%-75.9%). Among 36.3% (210/578) patients classified to the observation zone, 4.3% (9/210) had an adjudicated index MI. An optimized 0/2-h algorithm increased efficacy to 60.0% (347/578) while achieving an NPV of 99.4% (95% CI: 97.9%-99.9%) and PPV of 74.4% (95% CI: 58.8, 86.5%) for index MI.
CONCLUSIONS: The original Australian and optimized 0/2-h algorithms for i-STAT POC hs-cTnI measurement had high NPV and efficacy in a multisite U.S.
TRIAL REGISTRATION: Trial Registration: NCT06899776.
参考来源
- Mahler SA, Ashburn NP, Villenthi A, et al. Validation of a 0/2-Hour Point-Of-Care High Sensitivity Troponin Algorithm: A Multisite US Study. Acad Emerg Med. 2026. PMID: 42470147. doi:10.1111/acem.70379
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。